|
|
Post by mango on Jun 11, 2019 12:19:23 GMT -5
With the Brazil approval of Afrezza as an ultrarapid insulin, does that mean that Afrezza is now officially the world's one and only ultrarapid acting insulin? I think so. Anyone know of any others? I don't.
Looks like FDA and ADA have some catching up to do.
|
|
|
|
Post by #NoMoreNeedles on Jun 11, 2019 12:44:39 GMT -5
Lilly coming soon ...
|
|
|
|
Post by mango on Jun 11, 2019 13:23:34 GMT -5
Lilly has an ultra-rapid acting insulin that matches physiologic insulin like Afrezza does? |
|
|
|
Post by matt on Jun 11, 2019 14:25:18 GMT -5
Fiasp is already on the market in Brazil. I don't know if they advertise it as "ultra rapid" or not, but I assume they would.
|
|
|
|
Post by mango on Jun 11, 2019 14:43:58 GMT -5
Fiasp is already on the market in Brazil. I don't know if they advertise it as "ultra rapid" or not, but I assume they would. Don't think they do. |
|
|
|
Post by celo on Jun 11, 2019 14:57:04 GMT -5
|
|
|
|
Post by mango on Jun 11, 2019 15:31:28 GMT -5
Was it approved as an ultra-rapid? Novo marketed as one (like in that article) but am not aware of it being approved as one in any country. |
|
|
|
Post by akemp3000 on Jun 11, 2019 15:45:10 GMT -5
A distinction needs to be made that somehow combines ultra-rapid action on the front end with the controlled shorter action exit on the back end. Both are extremely important to diabetics and knowledge of such would drive sales. If there were a way to highlight the "dual" action, then Afrezza truly stands alone with no competition anywhere in sight.
|
|
|
|
Post by golfeveryday on Jun 11, 2019 17:48:38 GMT -5
A distinction needs to be made that somehow combines ultra-rapid action on the front end with the controlled shorter action exit on the back end. Both are extremely important to diabetics and knowledge of such would drive sales. If there were a way to highlight the "dual" action, then Afrezza truly stands alone with no competition anywhere in sight. post of the day for sure 👍🏻 |
|
|
|
Post by letitride on Jun 11, 2019 20:00:34 GMT -5
Dual action sums it up nicely.
|
|
|
|
Post by peppy on Jun 11, 2019 20:20:35 GMT -5
Fiasp is already on the market in Brazil. I don't know if they advertise it as "ultra rapid" or not, but I assume they would.  |
|
|
|
Post by prcgorman2 on Jun 11, 2019 21:29:03 GMT -5
So is NoMoreNeedles a play on words such that we wouldn’t want you to needle us longs any more? Not saying you’re not long. You don’t post your sentiment so I don’t know either way [and you can lie of course]. And really I kind of respect shorts for making money on us bagholders [yes, I am a buy-and-hold long bagholder], but I’m trying to remember the last time you weren’t posting something that would needle a long and I can’t think of any, but I’m not really keeping track either. It’s just this is like the 3rd or 4th post in a row that is either ruthlessly cynical or just kind of plain mean. Sports complains about us who complain about MK and I complain about people mocking MNKD management or Afrezza. Bleh. This is getting old. |
|
|
|
Post by buyitonsale on Jun 11, 2019 23:44:59 GMT -5
"f there were a way to highlight the "dual" action, then Afrezza truly stands alone with no competition anywhere in sight"
Let's start over...
remember Afrezza PK PD profile graph over healthy insulin response vs other insulins?
Yes, the one Al Mann was holding in his hand?
Yes, the graph that started it all.
Yes, the reason that you are all here talking about MNKD.
I do.
|
|
